



ASX ANNOUNCEMENT

10 November 2021

AGM Presentation

10 November 2021: In advance of this afternoon's Annual General Meeting of shareholders to be held at 2:00pm, and in accordance with ASX Listing Rule 3.13.3, Cann Group Limited (CAN:ASX) is pleased to provide a copy of the presentation that will be made to shareholders at the AGM.

This presentation has been authorised for release by the Board of Directors, Cann Group Limited.

For all media enquiries please contact:

Matthew Wright
NWR Communications
+61 451 896 420
matt@nwrcommunications.com.au

For all other information please contact:

Peter Crock
CEO
Cann Group Limited
+61 3 9095 7088
contact@canngrouplimited.com

Clive Fanning
Head of Investor Relations
Cann Group Limited
+61 3 9095 7088
clive.fanning@canngrouplimited.com

About Cann Group

Cann Group Limited (ABN 25 603 949 739) is building a world-class business focused on breeding, cultivating, manufacturing and supplying medicinal cannabis for sale and use within Australia and for approved overseas export markets. Cann also owns Satipharm, a Europe-based business exclusively licensed to manufacture, develop and market the proprietary Gelpell delivery system for cannabinoids. Cann has established research and cultivation facilities in Melbourne and is developing a state-of-the-art cultivation and manufacturing facility near Mildura, Victoria. Cann Group has established a leading position in plant genetics, breeding, extraction, analysis and production techniques required to facilitate the supply of medicinal cannabis for a range of diseases and medical conditions. The Company is commercialising a range of imported and locally sourced and manufactured medicinal cannabis products.

Learn more at: www.canngrouplimited.com | www.satipharm.com



CANN
GROUP LIMITED

Annual General Meeting

2pm Wednesday 10 November, 2021

Allan McCallum, AO | Chairman
Peter Crock | CEO

Disclaimer

This AGM presentation (Presentation) has been prepared by Cann Group Limited (ABN 25 603 949 739) (Cann).

Summary information

This Presentation contains summary information about Cann and its activities which is current as at the date of this Presentation. The information provided in this Presentation pertaining to Cann and its business assets, strategy and operations is for general informational purposes only.

Future performance

This Presentation contains certain 'forward looking statements', including but not limited to projections, guidance on future revenues and other potential synergies and estimates about the future performance of Cann. Forward looking statements can generally be identified by the use of forward-looking words such as, 'expect', 'anticipate', 'likely', 'intend', 'should', 'could', 'may', 'predict', 'plan', 'propose', 'will', 'believe', 'forecast', 'estimate', 'target' 'outlook', 'guidance', 'potential' and other similar expressions within the meaning of securities laws of applicable jurisdictions.

The forward-looking statements contained in this Presentation are not guarantees or predictions of future performance and involve known and unknown risks and uncertainties and other factors, many of which are beyond the control of Cann, and may involve significant elements of subjective judgement and assumptions as to future events which may or may not be correct. No representation, warranty or assurance (express or implied) is given or made in relation to any forward-looking statement by any person (including Cann). There can be no assurance that actual outcomes will not differ materially from these forward-looking statements. A number of important factors could cause actual results or performance to differ materially from the forward-looking statements. The forward-looking statements are based on information available to Cann as at the date of this Presentation.

Except as required by law or regulation (including the ASX Listing Rules), Cann undertakes no obligation to provide any additional or updated information whether as a result of new information, future events or results or otherwise. Indications of, and guidance or outlook on, future earnings or financial position or performance are also forward-looking statements.

Past performance

Investors should note that past performance, including any historical information in this Presentation cannot be relied upon as an indicator of (and provides no guidance as to) future Cann performance including future share price performance.

All rights reserved

Several photographs contained in this Presentation are the property of Cann and are protected under copyright laws. No part of this Presentation may be reproduced, distributed, or transmitted in any form or by any means, including photocopying, recording, or other electronic or mechanical methods, without the prior written permission of the Company, except in the case of brief quotations embodied in critical reviews and certain other non-commercial uses permitted by copyright law.

Agenda

- 1 Introduction
- 2 Chairman's address
- 3 CEO's address
- 4 Q&A
- 5 Formal items of business



Our Board & CEO



MR ALLAN MCCALLUM,
AO

Chairman



MR PHILIP JACOBSEN

Deputy Chairman



MR DOUG RATHBONE,
AM

Non-executive Director



MR GEOFF PEARCE

Non-executive Director



MS JENNI PILCHER

Non-executive Director



MR JOHN SHARMAN

Non-executive Director



MR PETER CROCK

Chief Executive Officer

Formal business of AGM



CANN
GROUP LIMITED

Item 1 | Financial statements and reports

To receive the financial report, directors' report and auditor's report for the Company and its controlled entities for the financial year ended 30 June 2021.

CANN
GROUP LIMITED



Chairman's address

Allan McCallum, AO



Corporate growth

GROWTH STRATEGY SUPPORTED BY INVESTORS

Capital raisings pave the way for Cann's fully integrated supply chain strategy.

TIER 1 BANK DEBT FINANCE

Secured \$50m debt facility with NAB.

DEVELOPING AN END-TO-END CAPABILITY

Cann to deliver cultivation, testing, drying, extraction, formulation and more.



Satipharm

SATIPHARM ACQUISITION POSITIONS CANN TO:

- Access rapidly growing CBD markets.
- Fast-track development of THC medicinal cannabis products.
- Become an Australian leader in the over-the-counter low-dose CBD market.

satipharm

CANN
GROUP LIMITED



World class facilities

MILDURA FACILITY IS
NEARING COMPLETION

Large scale, medical grade, cGMP
manufacturing facility.

FOCUS ON IMPROVED
EFFICIENCIES & INNOVATION

UPGRADE AT SOUTHERN
FACILITY



Global demand

IUVO THERAPEUTICS

- Partnership established with iuvo, a leading German importer & distributor.
- Cann delivered first shipment of 20,000 units.

REGULATORY CHANGES & EVIDENCE CONTINUES TO EVOLVE

GROWTH IN DEMAND EXPECTED TO CONTINUE

CANN
GROUP LIMITED



CEO's address


Peter Crock



Establishes Cann's capabilities
and scale related efficiencies.



Cultivation, GMP extraction,
manufacturing and analytical
laboratory.



Aiming to be an employer of
choice in the Sunraysia region.

**Mildura
nears
completion**



Upgrades & commercial

UPGRADE AT SOUTHERN
FACILITY ENABLES CGMP
PACKED FLOWER

B2B STRATEGY CONTINUES
WITH EUROPE/UK FOCUS

MULTIPLE REVENUE
OPPORTUNITIES WITH LOCAL
CUSTOMERS



Satipharm

OPENS B2C OPPORTUNITY

CAPSULE TECHNOLOGY TO
PROMOTE CONFIDENCE

FAST TRACKS DEVELOPMENT OF
THC-BASED FORMULATIONS

S3 OVER-THE-COUNTER
OPPORTUNITY PROGRESSING

A photograph of industrial equipment, possibly a large tank or reactor, with various pipes and valves. A green rectangular overlay is positioned in the center-left of the image, containing the text 'R&D partnerships' in white.

R&D partnerships

RESEARCH PROGRAMS ENSURE CANN IS LEADING INNOVATION IN THE SECTOR:

- Agriculture Victoria – genetics
- La Trobe University – nutrition requirements
- NSW DPI – cultivation techniques
- CSIRO – cannabinoid isolation & manufacturing
- Monash Medicines Innovation Centre – novel formulation & new IP
- Olivia Newton John Cancer Research Institute, La Trobe School of Cancer Medicine & Austin Health – trial in advanced cancer patients
- Murdoch Children’s Research Institute – study into severe Tourette’s syndrome



Outlook FY22

CONTINUALLY GROWING
ACCEPTANCE OF MEDICINAL
CANNABIS

MILDURA FACILITY
COMMISSIONING BRINGING
VARIOUS NEW
OPPORTUNITIES

FOCUS ON DELIVERY FOR ALL
STAKEHOLDERS



Q&A



CANN
GROUP LIMITED

Resolutions for voting

Items 2 to 5

Resolution 2 | Adoption of Remuneration Report

That, pursuant to and in accordance with section 250R(2) of the Corporations Act, the Remuneration Report for the financial year ending 30 June 2021 as set out in pages 23 to 32 (inclusive) of the Annual Report be adopted.

Proxy votes

	For	Open	Against	Total Valid Available Votes	% of Issued Capital	Abstain
Votes	33,661,998	2,355,520	2,035,886	38,053,404	10.91%	160,515
Percentage	88.46%	6.19%	5.35%			

Resolution 3 | Re-election of Director

That Mr Doug Rathbone, a Director who retires from office in accordance with Rule 50.2 of the Company's Constitution and being eligible for re-election, be re-elected a Director of the Company.

Proxy votes

	For	Open	Against	Total Valid Available Votes	% of Issued Capital	Abstain
Votes	52,615,955	3,151,675	1,176,980	56,944,610	16.32%	196,488
Percentage	92.40%	5.53%	2.07%			

Resolution 4 | Re-election of Director

That Mr John Sharman, a Director who was appointed to fill a casual vacancy in accordance with Rule 49.1 of the Company's Constitution until this Annual General Meeting and being eligible for re-election, be re-elected a Director of the Company.

Proxy votes

	For	Open	Against	Total Valid Available Votes	% of Issued Capital	Abstain
Votes	52,748,053	3,151,948	1,046,859	56,946,860	16.32%	194,238
Percentage	92.63%	5.53%	1.84%			

Resolution 5 | Approval of amendments to Constitution

That, in accordance with section 136(2) of the Corporations Act the Constitution of the Company be amended as set out in the amended Constitution tabled at the Annual General Meeting convened by this Notice of Annual General Meeting and signed by the Chairman of the meeting for the purpose of identification.

Proxy votes

	For	Open	Against	Total Valid Available Votes	% of Issued Capital	Abstain
Votes	52,404,277	3,167,974	1,278,510	56,850,761	16.30%	290,337
Percentage	92.18%	5.57%	2.25%			



Meeting close

CONTACTS

Clive Fanning
Head of Investor Relations

Cann Group Limited
+61 3 9095 7088
contact@canngrouponlimited.com

Matthew Wright
Investor / Media Relations

NWR Communications
+61 (0)451 896 420
matt@nwrcommunications.com.au